Wayrilz (Rezabrutinib) is a kinase inhibitor that primarily acts on Bruton's Tyrosine Kinase (BTK). First approved in the United States in 2025, this medication is indicated for the treatment of persistent or chronic immune thrombocytopenia (ITP) in adults who have had an inadequate response to previous treatments.

Standard Usage Instructions

Recommended dosage: 400 mg orally, twice daily.

Swallow the tablet whole with water; it may be taken with or without food.

Do not cut, crush, or chew the tablets.

It is recommended to take the medication at approximately the same times each day.

Precautions for Medication Use

If gastrointestinal symptoms occur, taking the medication with food may improve tolerability.

If a dose is missed, take the missed dose as soon as possible on the same day, with an interval of at least 2 hours from the next regularly scheduled dose.

If antacids or histamine H2 receptor antagonists are used, Rezabrutinib should be taken at least 2 hours before these medications.

Dosage Adjustment of Wayrilz (Rezabrutinib)

Hepatotoxicity Monitoring and Dosage Adjustment

Evaluate bilirubin and transaminases at baseline and as clinically needed.

If abnormal liver function test results occur, monitor liver function and clinical signs of hepatotoxicity more frequently.

If drug-induced liver injury (DILI) is suspected, discontinue the medication temporarily.

After a confirmed diagnosis of DILI, discontinue the medication permanently.

CYP3A Inhibitors

Avoid concurrent use with strong or moderate CYP3A inhibitors.

If short-term use (e.g., anti-infective agents for 7 days or less) is necessary, interrupt Rezabrutinib treatment.

Avoid concurrent consumption of grapefruit, star fruit and their products, and Seville oranges.

Gastric Acid-Reducing Agents

Proton pump inhibitors: Avoid concurrent use.

Antacids or H2 receptor antagonists: Rezabrutinib should be taken at least 2 hours before these medications.

Medication Use in Special Populations for Wayrilz (Rezabrutinib)

Patients with Hepatic Impairment

Moderate or severe hepatic impairment (Child-Pugh Class B-C): Avoid use.

Mild hepatic impairment (Child-Pugh Class A): No dosage adjustment is required.

Patients with Renal Impairment

Severe renal impairment: Avoid use (no studies have been conducted in this patient population).

Mild or moderate renal impairment: No dosage adjustment is required.

Pregnant Women

Based on animal data, Rezabrutinib may cause fetal harm.

Verify the pregnancy status of women of reproductive potential before initiating treatment.

Women of reproductive potential are advised to use effective contraceptive measures during treatment and for 1 week after the last dose.

Lactating Women

There are no data on whether Rezabrutinib or its metabolites are present in human milk or animal milk.

Lactating women are advised not to breastfeed during treatment with Rezabrutinib and for at least 1 week after the last dose.